Author

Jung Hyun Her

Observed names: Her, Jung, J. Her

Observed institution: Green Cross (South Korea)

ORCID: 0000-0002-1044-2430

Observed ORCID: 0000-0002-1044-2430

OpenAlex ID: A5038583512

Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

2016 · Yaewon Yang, Okjae Lim, et al. · Cancer Immunology Research · 155

Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain

2015 · Se Jeong Lee, Won Young Kang, et al. · BMC Cancer · 82

PDF

GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In Vivo

2013 · Okjae Lim, Yuna Lee, et al. · PLoS ONE · 80

PDF

Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy

2018 · Bokyung Min, Hana Choi, et al. · Immune Network · 60

PDF

Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma

2019 · Young Bae Choi, Meong Hi Son, et al. · PLoS ONE · 18

PDF

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy

2022 · Jung Hyun Her, Dominik Pretscher, et al. · Cancer Immunology Immunotherapy · 13

PDF

Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study

2021 · Jong Man Kim, Sung Yoo Cho, et al. · Annals of Hepato-Biliary-Pancreatic Surgery · 12

PDF

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

2019 · Jung Hyun Her, Dominik Pretscher, et al. · Blood · 2

Supplementary Tables S1~S2 from Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

2023 · Yaewon Yang, Okjae Lim, et al.

Supplementary Figures S1~S5 from Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

2023 · Yaewon Yang, Okjae Lim, et al.

Data from Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

2023 · Yaewon Yang, Okjae Lim, et al.

Post-transfusion kinetics of allogeneic natural killer cells in patients with malignant lymphoma or advanced solid tumors

2018 · O. Lim, H. Chung, et al. · Cytotherapy

Clinical efficacy of killer cell immunoglobulin-like receptor ligand-mismatched allogeneic natural killer cells in patients with malignant lymphoma or advanced solid tumors

2017 · O. Lim, H. Choi, et al. · Cytotherapy

Effect of MG4101, random donor derived, ex vivo-expanded NK cells, in combination with Rituximab in B cell Lymphoma model

2017 · J. Her, E. Lee, et al. · Cytotherapy

Additional file 1: of Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain

2015 · Lee, Se, Kang, Won, et al. · Figshare

Therapeutic efficacy of ex vivo expanded allogeneic natural killer cells in mouse neuroblastoma model

2014 · O. Lim, J. Her, et al. · Cytotherapy

Aging and Cancer : Adoptive transfer of interleukin-15 treated natural killer cells can reduce tumor size and increase survival in a murine solid tumor model

2008 · Jung Hyun Her, Nam Kyung Kim, et al. · 생화학분자생물학회 춘계학술발표논문집

Works count: 17

Citation count: 422

H-index: 7

I10-index: 7